{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:22:42Z","timestamp":1780392162786,"version":"3.54.1"},"reference-count":26,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2023.14113","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T12:11:36Z","timestamp":1698063096000},"source":"Crossref","is-referenced-by-count":4,"title":["Enteral lorlatinib after immune hyperprogression as a treatment option for anaplastic lymphoma kinase\u2011positive non\u2011small cell lung cancer: A case report"],"prefix":"10.3892","volume":"26","author":[{"given":"Huan","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, General Hospital of Western Theater Command, Chengdu, Sichuan 610083, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, General Hospital of Western Theater Command, Chengdu, Sichuan 610083, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangqing","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, General Hospital of Western Theater Command, Chengdu, Sichuan 610083, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, General Hospital of Western Theater Command, Chengdu, Sichuan 610083, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenliang","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, General Hospital of Western Theater Command, Chengdu, Sichuan 610083, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2023,10,23]]},"reference":[{"key":"key20231122104227_b1-ol-26-6-14113","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1016\/j.jtho.2019.08.003","article-title":"Monitoring therapeutic response and resistance: Analysis of circulating tumor DNA in patients with ALK+ lung cancer","volume":"14","author":"Horn","year":"2019","journal-title":"J Thorac Oncol"},{"key":"key20231122104227_b2-ol-26-6-14113","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: Results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol"},{"key":"key20231122104227_b3-ol-26-6-14113","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11523-020-00702-4","article-title":"Brain penetration of lorlatinib: Cumulative incidences of CNS and non-CNS progression with lorlatinib in patients with previously treated ALK-positive non-small-cell lung cancer","volume":"15","author":"Bauer","year":"2020","journal-title":"Target Oncol"},{"key":"key20231122104227_b4-ol-26-6-14113","article-title":"FDA approves lorlatinib for metastatic ALK-positive NSCLC","author":"US FDA"},{"key":"key20231122104227_b5-ol-26-6-14113","article-title":"Crizotinib prescribing information","author":"US FDA"},{"key":"key20231122104227_b6-ol-26-6-14113","article-title":"Alectinib prescribing information","author":"US FDA"},{"key":"key20231122104227_b7-ol-26-6-14113","article-title":"Lorlatinib prescribing information","author":"US FDA"},{"key":"key20231122104227_b8-ol-26-6-14113","first-page":"1075641","article-title":"A case of non-small cell lung cancer with possible \u2018disease flare\u2019 on nivolumab treatment","volume":"2016","author":"Chubachi","year":"2016","journal-title":"Case Rep Oncol Med"},{"key":"key20231122104227_b9-ol-26-6-14113","doi-asserted-by":"publisher","first-page":"100923","DOI":"10.1016\/j.gore.2022.100923","article-title":"Non-gestational choriocarcinoma with hyperprogression on pembrolizumab: A case report and review of the literature","volume":"39","author":"Kazemi","year":"2022","journal-title":"Gynecol Oncol Rep"},{"key":"key20231122104227_b10-ol-26-6-14113","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1","volume":"23","author":"Champiat","year":"2017","journal-title":"Clin Cancer Res"},{"key":"key20231122104227_b11-ol-26-6-14113","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-17-1990","article-title":"Hyperprogressors after immunotherapy: Analysis of genomic alterations associated with accelerated growth rate","volume":"23","author":"Kato","year":"2017","journal-title":"Clin Cancer Res"},{"key":"key20231122104227_b12-ol-26-6-14113","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/1759-7714.13370","article-title":"Factors related to rapid progression of non-small cell lung cancer in Chinese patients treated using single-agent immune checkpoint inhibitor treatment","volume":"11","author":"Zhang","year":"2020","journal-title":"Thorac Cancer"},{"key":"key20231122104227_b13-ol-26-6-14113","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1159\/000503095","article-title":"Performance status assessment by using ECOG (eastern cooperative oncology group) score for cancer patients by oncology healthcare professionals","volume":"12","author":"Azam","year":"2019","journal-title":"Case Rep Oncol"},{"key":"key20231122104227_b14-ol-26-6-14113","doi-asserted-by":"publisher","first-page":"102969","DOI":"10.1016\/j.critrevonc.2020.102969","article-title":"A user's guide to lorlatinib","volume":"151","author":"Nagasaka","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20231122104227_b15-ol-26-6-14113","doi-asserted-by":"publisher","first-page":"3493349","DOI":"10.1073\/pnas.1420785112","article-title":"PF-06463922 is a potent and selective next-generation ROS1\/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations","volume":"112","author":"Zou","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20231122104227_b16-ol-26-6-14113","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1200\/JCO.21.02278","article-title":"Post hoc analysis of lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non-small-cell lung cancer from the phase III CROWN study","volume":"40","author":"Solomon","year":"2022","journal-title":"J Clin Oncol"},{"key":"key20231122104227_b17-ol-26-6-14113","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"key":"key20231122104227_b18-ol-26-6-14113","doi-asserted-by":"publisher","first-page":"4720","DOI":"10.1021\/jm500261q","article-title":"Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations","volume":"57","author":"Johnson","year":"2014","journal-title":"J Med Chem"},{"key":"key20231122104227_b19-ol-26-6-14113","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00280-021-04368-1","article-title":"Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase\/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants","volume":"89","author":"Hibma","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20231122104227_b20-ol-26-6-14113","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.3390\/ijms20112674","article-title":"Hyperprogression under Immunotherapy","volume":"20","author":"Frelaut","year":"2019","journal-title":"Int J Mol Sci"},{"key":"key20231122104227_b21-ol-26-6-14113","doi-asserted-by":"publisher","first-page":"v464","DOI":"10.1093\/annonc\/mdx380.009","article-title":"Hyperprogressive disease (HPD) is frequent in non-small cell lung cancer (NSCLC) patients (pts) treated with anti PD1\/PD-L1 monoclonal antibodies (IO)","volume":"28","author":"Ferrara","year":"2017","journal-title":"Ann Oncol"},{"key":"key20231122104227_b22-ol-26-6-14113","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1200\/JCO.2016.71.9476","article-title":"Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH)","volume":"35","author":"Peters","year":"2017","journal-title":"J Clin Oncol"},{"key":"key20231122104227_b23-ol-26-6-14113","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.lungcan.2018.09.010","article-title":"Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer","volume":"125","author":"Liu","year":"2018","journal-title":"Lung Cancer"},{"key":"key20231122104227_b24-ol-26-6-14113","doi-asserted-by":"publisher","first-page":"e004273","DOI":"10.1136\/jitc-2021-004273","article-title":"Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials","volume":"10","author":"Kang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"key20231122104227_b25-ol-26-6-14113","first-page":"100044","article-title":"Esophageal stricture caused by ALK-positive NSCLC esophageal metastasis resolved after a few days of lorlatinib therapy without stent placement","volume":"1","author":"Longo","year":"2020","journal-title":"JTO Clin Res Rep"},{"key":"key20231122104227_b26-ol-26-6-14113","doi-asserted-by":"publisher","first-page":"e00796","DOI":"10.1002\/rcr2.796","article-title":"Enteral lorlatinib after alectinib as a treatment option in anaplastic lymphoma kinase-positive non-small cell lung cancer with triple problems: Carcinomatous meningitis, poor performance status, and dysphagia-a case report","volume":"9","author":"Sasaki","year":"2021","journal-title":"Respirol Case Rep"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T08:48:07Z","timestamp":1700642887000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2023.14113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,23]]},"references-count":26,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,10,23]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2023.14113","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,23]]},"article-number":"526"}}